Brandon Essink

Velocity Clinical Research (United States)

Also affiliated with Meridian Clinical Research

MedicineAgricultural and Biological Sciences

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase”.

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

New England Journal of Medicine(2021)10.1056/nejmoa2113017

N/A

8.3DataRank · unranked

662 citations

Lindsey R. Baden, Brandon Essink, Susanne Doblecki‐Lewis, Judith M. Martin, Evan J. Anderson +33 more

Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons

Clinical Infectious Diseases(2024)10.1093/cid/ciae010

N/A

4.1DataRank · unranked

164 citations

Alberto Papi, Eugene Athan, Robert G. Feldman, Joanne M. Langley, Dong‐Gun Lee +95 more

Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial

The Journal of Infectious Diseases(2022)10.1093/infdis/jiac188

N/A

0.686DataRank · unranked

21 citations

Lindsey R. Baden, Brandon Essink, David C. Montefiori, Adrian McDermont, Richard Rupp +19 more

Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial

Open Forum Infectious Diseases(2024)10.1093/ofid/ofae689

N/A

0.444DataRank · unranked

8 citations

Xiaowei Wang, Lindsey R. Baden, Hana M. El Sahly, Brandon Essink, Peter B. Gilbert +13 more

Associations of Immunogenicity and Reactogenicity After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine in the COVE and TeenCOVE Trials

Clinical Infectious Diseases(2022)10.1093/cid/ciac780

N/A

0.312DataRank · unranked

7 citations

Lindsey R. Baden, Hana M. El Sahly, Brandon Essink, Kashif Ali, Gary Berman +10 more

Vaccine efficacy of NVX-CoV2373 against SARS-CoV-2 infection in adolescents in the USA: an ancillary study to a phase 3, observer-blinded, randomised, placebo-controlled trial

The Lancet Microbe(2025)10.1016/j.lanmic.2024.100984

N/A

0.241DataRank · unranked

4 citations

Elizabeth R. Brown, Monica A. McArthur, Stephanie J. Schrag, Melissa Arvay, Mike Humphrys +36 more

1939. Who to Boost When: An Analysis of Dosing Interval and Age on COVID-19 Outcomes in the COVE Trial During the Delta and Omicron Waves

Open Forum Infectious Diseases(2023)10.1093/ofid/ofad500.2470

N/A

0.208DataRank · unranked

3 citations

Xiaowei Wang, Peter B. Gilbert, Lindsey R. Baden, Hana M. El Sahly, Brandon Essink +10 more

Long-term safety and efficacy of COVE study open-label and booster phases

Research Square(2024)10.21203/rs.3.rs-3900939/v1

N/A

0DataRank · unranked

0 citations

Hana M. El Sahly, Brandon Essink, Dean Follmann, Gregory Hachigian, Cynthia Strout +19 more

Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial

JAMA Network Open(2022)10.1001/jamanetworkopen.2022.15984

N/A

0DataRank · unranked

4 citations

Lindsey R. Baden, Hana M. El Sahly, Brandon Essink, Kathleen M. Neuzil, Lawrence Corey +7 more